Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 2/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21904091 | 0.82 | CPT1A (0.37) | CPT1ACPT1BCPT2OPRL1 | |
| SCHEMBL31436564 | 0.80 | KCNK2 (0.36) | C5AR1OPRL1POLB | |
| SCHEMBL25316717 | 0.79 | C5AR1 (0.41) | C5AR1OPRL1POLB | |
| SCHEMBL30507035 | 0.79 | C5AR1 (0.41) | C5AR1OPRL1POLB | |
| SCHEMBL28367574 | 0.79 | PSMB8 (0.39) | — | |
| SCHEMBL30804497 | 0.76 | OPRL1 (0.42) | OPRL1 | |
| SCHEMBL21904215 | 0.75 | CALCRL (0.34) | OPRL1 | |
| SCHEMBL21904383 | 0.74 | CALCRL (0.32) | — | |
| SCHEMBL30468521 | 0.74 | CALCRL (0.32) | — | |
| SCHEMBL31436447 | 0.73 | DDR1 (0.41) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110769821-B | Spiro indolines as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3638227-B1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-08-10 | — | — | EP | disclosed |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | UCB Biopharma SRL (BE) | 2020-05-07 | — | — | US | disclosed |
| CN-110769821-A | Spirocyclic indolines as IL-17 modulators | UCB生物制药私人有限公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | IL17A, IL2, IL18 | CPT1A 1088/4885CPT1B 3319/4885CPT2 1856/4885 |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | IL17A, IL2, IL18 | CPT1A 1088/4885CPT1B 3319/4885CPT2 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.